{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:34:53Z","timestamp":1773153293056,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2022.13324.BD"],"award-info":[{"award-number":["2022.13324.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Distinguishing benign from malignant adrenocortical tumors (ACT) is not always easy, particularly for tumors with unclear malignant potential based on the histopathological features comprised of  the Weiss score. Previous studies reported the potential utility of immunohistochemistry (IHC) markers to recognize malignancy, in particular the Insulin-like growth factor 2 (IGF2) and the proliferation marker, Ki-67. However, this information was not compiled before. Therefore, this review aimed to collect the evidence on the potential diagnosis utility of IGF2 and Ki-67 IHC staining. Additionally, a meta-analysis was performed to assess the Ki-67 accuracy to identify adrenocortical carcinoma. The systematic review and meta-analysis were conducted according to the PRISMA guidelines. From the 26 articles included in the systematic review, 21 articles provided individual data for IGF2 (<jats:italic>n<\/jats:italic>\u2009=\u20092) or for Ki-67 (<jats:italic>n<\/jats:italic>\u2009=\u200919), while 5 studies assessed both markers. IGF2 staining was positive in most carcinomas, in contrast to adenomas. However, the different immunostaining evaluation methods adopted among the studies impeded to perform a meta-analysis to assess IGF2 diagnostic accuracy. In contrast, for the most commonly used cut-off value of 5% stained cells, Ki-67 showed pooled specificity, sensitivity and log diagnostic odds ratio of 0.98 (95% CI 0.95 to 0.99), 0.82 (95% CI 0.65 to 0.92) and 4.26 (95% CI 3.40 to 5.12), respectively. At the 5% cut-off, Ki-67 demonstrated an excellent specificity to recognize malignant ACT. However. the moderate sensitivity observed indicates the need for further studies exploring alternative threshold values. Additionally, more studies using similar approaches are needed to assess the diagnostic accuracy of IGF2.<\/jats:p>\n          <jats:p>\n            <jats:bold>Registration code in PROSPERO:<\/jats:bold> CRD42022370389.<\/jats:p>","DOI":"10.1007\/s11154-025-09945-w","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T20:34:22Z","timestamp":1738355662000},"page":"261-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The differential diagnosis of adrenocortical tumors: systematic review of Ki-67 and IGF2 and meta-analysis of Ki-67"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0287-5690","authenticated-orcid":false,"given":"Sofia B.","family":"Oliveira","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5918-8871","authenticated-orcid":false,"given":"Mariana Q.","family":"Machado","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0145-2642","authenticated-orcid":false,"given":"Diana","family":"Sousa","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6947-4560","authenticated-orcid":false,"given":"Sofia S.","family":"Pereira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5555-7004","authenticated-orcid":false,"given":"Duarte","family":"Pignatelli","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"issue":"1","key":"9945_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12022-022-09710-8","volume":"33","author":"O Mete","year":"2022","unstructured":"Mete O, et al. Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. Endocr Pathol. 2022;33(1):155\u201396. https:\/\/doi.org\/10.1007\/s12022-022-09710-8.","journal-title":"Endocr Pathol"},{"issue":"11","key":"9945_CR2","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"Fassnacht M, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1476\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2099.","journal-title":"Ann Oncol"},{"issue":"11","key":"9945_CR3","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","volume":"49","author":"TM Kerkhofs","year":"2013","unstructured":"Kerkhofs TM, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579\u201386. https:\/\/doi.org\/10.1016\/j.ejca.2013.02.034.","journal-title":"Eur J Cancer"},{"key":"9945_CR4","doi-asserted-by":"publisher","first-page":"100759","DOI":"10.1016\/j.ctarc.2023.100759","volume":"37","author":"R Libe","year":"2023","unstructured":"Libe R, Huillard O. Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease. Cancer Treat Res Commun. 2023;37:100759. https:\/\/doi.org\/10.1016\/j.ctarc.2023.100759.","journal-title":"Cancer Treat Res Commun"},{"issue":"2","key":"9945_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"Else T, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35(2):282\u2013326. https:\/\/doi.org\/10.1210\/er.2013-1029.","journal-title":"Endocr Rev"},{"issue":"4","key":"9945_CR6","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, et al. European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the european network for the study of adrenal tumors. Eur J Endocrinol. 2018;179(4):G1\u201346. https:\/\/doi.org\/10.1530\/EJE-18-0608.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"9945_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3390\/biomedicines9020175","volume":"9","author":"AK Lam","year":"2021","unstructured":"Lam AK. Adrenocortical carcinoma: updates of clinical and pathological features after renewed world health organisation classification and pathology staging. Biomedicines. 2021;9(2):175. https:\/\/doi.org\/10.3390\/biomedicines9020175.","journal-title":"Biomedicines"},{"issue":"2","key":"9945_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/PAS.0000000000000943","volume":"42","author":"O Mete","year":"2018","unstructured":"Mete O, et al. Diagnostic and prognostic biomarkers of adrenal cortical carcinoma. Am J Surg Pathol. 2018;42(2):201\u201313. https:\/\/doi.org\/10.1097\/PAS.0000000000000943.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"9945_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/00000478-198903000-00004","volume":"13","author":"LM Weiss","year":"1989","unstructured":"Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989;13(3):202\u20136. https:\/\/doi.org\/10.1097\/00000478-198903000-00004.","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"9945_CR10","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/j.humpath.2015.08.012","volume":"46","author":"E Duregon","year":"2015","unstructured":"Duregon E, et al. Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases. Hum Pathol. 2015;46(12):1799\u2013807. https:\/\/doi.org\/10.1016\/j.humpath.2015.08.012.","journal-title":"Hum Pathol"},{"issue":"17","key":"9945_CR11","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.3390\/cancers13174383","volume":"13","author":"CL Vietor","year":"2021","unstructured":"Vietor CL, et al. How to differentiate benign from malignant adrenocortical tumors? Cancers (Basel). 2021;13(17):4383. https:\/\/doi.org\/10.3390\/cancers13174383.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"9945_CR12","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/his.12283","volume":"64","author":"C Wang","year":"2014","unstructured":"Wang C, et al. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers. Histopathology. 2014;64(4):567\u201376. https:\/\/doi.org\/10.1111\/his.12283.","journal-title":"Histopathology"},{"issue":"6","key":"9945_CR13","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/BF03347480","volume":"27","author":"C Pohlink","year":"2004","unstructured":"Pohlink C, et al. Does tumor heterogeneity limit the use of the Weiss criteria in the evaluation of adrenocortical tumors? J Endocrinol Invest. 2004;27(6):565\u20139. https:\/\/doi.org\/10.1007\/BF03347480.","journal-title":"J Endocrinol Invest"},{"key":"9945_CR14","doi-asserted-by":"publisher","first-page":"1218686","DOI":"10.3389\/fendo.2023.1218686","volume":"14","author":"L Urusova","year":"2023","unstructured":"Urusova L, et al. The new histological system for the diagnosis of adrenocortical cancer. Front Endocrinol (Lausanne). 2023;14:1218686. https:\/\/doi.org\/10.3389\/fendo.2023.1218686.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"9945_CR15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.rec.2021.07.010","volume":"74","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74(9):790\u20139. https:\/\/doi.org\/10.1016\/j.rec.2021.07.010.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"6","key":"9945_CR16","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3348\/kjr.2015.16.6.1175","volume":"16","author":"KW Kim","year":"2015","unstructured":"Kim KW, et al. Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers-part I. general guidance and tips. Korean J Radiol. 2015;16(6):1175\u201387. https:\/\/doi.org\/10.3348\/kjr.2015.16.6.1175.","journal-title":"Korean J Radiol"},{"key":"9945_CR17","doi-asserted-by":"publisher","first-page":"m2632","DOI":"10.1136\/bmj.m2632","volume":"370","author":"J-P Salameh","year":"2020","unstructured":"Salameh J-P, et al. Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist. BMJ. 2020;370:m2632. https:\/\/doi.org\/10.1136\/bmj.m2632.","journal-title":"BMJ"},{"issue":"3","key":"9945_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1365-2559.2006.02505.x","volume":"49","author":"A Schmitt","year":"2006","unstructured":"Schmitt A, et al. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology. 2006;49(3):298\u2013307. https:\/\/doi.org\/10.1111\/j.1365-2559.2006.02505.x.","journal-title":"Histopathology"},{"issue":"2","key":"9945_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1677\/ERC-08-0237","volume":"16","author":"PSH Soon","year":"2009","unstructured":"Soon PSH, et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer. 2009;16(2):573\u201383. https:\/\/doi.org\/10.1677\/ERC-08-0237.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"9945_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1530\/EC-13-0025","volume":"2","author":"SS Pereira","year":"2013","unstructured":"Pereira SS, et al. The emerging role of the molecular marker p27 in the differential diagnosis of adrenocortical tumors. Endocr Connect. 2013;2(3):137\u201345. https:\/\/doi.org\/10.1530\/EC-13-0025.","journal-title":"Endocr Connect"},{"issue":"7","key":"9945_CR21","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s12094-013-1130-1","volume":"16","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, et al. Expression of STAT3 and IGF2 in adrenocortical carcinoma and its relationship with angiogenesis. Clin Transl Oncol. 2014;16(7):644\u20139. https:\/\/doi.org\/10.1007\/s12094-013-1130-1.","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"9945_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/jso.24665","volume":"116","author":"A Babi\u0144ska","year":"2017","unstructured":"Babi\u0144ska A, et al. Diagnostic and prognostic role of SF1, IGF2, Ki67, p53, adiponectin, and leptin receptors in human adrenal cortical tumors. J Surg Oncol. 2017;116(3):427\u201333. https:\/\/doi.org\/10.1002\/jso.24665.","journal-title":"J Surg Oncol"},{"issue":"2","key":"9945_CR23","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s12020-019-02033-5","volume":"66","author":"SS Pereira","year":"2019","unstructured":"Pereira SS, et al. IGF2 role in adrenocortical carcinoma biology. Endocrine. 2019;66(2):326\u201337. https:\/\/doi.org\/10.1007\/s12020-019-02033-5.","journal-title":"Endocrine"},{"issue":"1","key":"9945_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/BF02739705","volume":"8","author":"AM McNicol","year":"1997","unstructured":"McNicol AM, et al. Proliferation in adrenocortical tumors: correlation with clinical outcome and p53 Status. Endocr Pathol. 1997;8(1):29\u201336. https:\/\/doi.org\/10.1007\/BF02739705.","journal-title":"Endocr Pathol"},{"issue":"4","key":"9945_CR25","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3109\/07435800009048609","volume":"26","author":"J Arola","year":"2000","unstructured":"Arola J, et al. p53 and Ki67 in adrenocortical tumors. Endocr Res. 2000;26(4):861\u20135. https:\/\/doi.org\/10.3109\/07435800009048609.","journal-title":"Endocr Res"},{"issue":"3","key":"9945_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/00022744-200109000-00004","volume":"9","author":"D Gupta","year":"2001","unstructured":"Gupta D, et al. Value of topoisomerase II \u03b1, mib-1, p53, e-cadherin, retinoblastoma gene protein product, and her-2\/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms. Appl Immunohistochem Mol Morphol. 2001;9(3):215\u201321. https:\/\/doi.org\/10.1097\/00022744-200109000-00004.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"1","key":"9945_CR27","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0090-4295(00)00852-9","volume":"57","author":"M Terzolo","year":"2001","unstructured":"Terzolo M, et al. Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. Urology. 2001;57(1):176\u201382. https:\/\/doi.org\/10.1016\/S0090-4295(00)00852-9.","journal-title":"Urology"},{"issue":"12","key":"9945_CR28","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1097\/00000478-200212000-00009","volume":"26","author":"S Aubert","year":"2002","unstructured":"Aubert S, et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol. 2002;26(12):1612\u20139. https:\/\/doi.org\/10.1097\/00000478-200212000-00009.","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"9945_CR29","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/sj.bjc.6600287","volume":"86","author":"GP Bernini","year":"2002","unstructured":"Bernini GP, et al. Apoptosis control and proliferation marker in human normal and neoplastic adrenocortical tissues. Br J Cancer. 2002;86(10):1561\u20135. https:\/\/doi.org\/10.1038\/sj.bjc.6600287.","journal-title":"Br J Cancer"},{"issue":"2","key":"9945_CR30","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0002-9440(10)63846-1","volume":"162","author":"TJ Giordano","year":"2003","unstructured":"Giordano TJ, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol. 2003;162(2):521\u201331. https:\/\/doi.org\/10.1016\/S0002-9440(10)63846-1.","journal-title":"Am J Pathol"},{"issue":"1\u20132","key":"9945_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.mce.2005.01.012","volume":"233","author":"S Kiiveri","year":"2005","unstructured":"Kiiveri S, et al. Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors. Mol Cell Endocrinol. 2005;233(1\u20132):47\u201356. https:\/\/doi.org\/10.1016\/j.mce.2005.01.012.","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"9945_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1442-2042.2005.00999.x","volume":"12","author":"K Takehara","year":"2005","unstructured":"Takehara K, et al. Proliferative activity and genetic changes in adrenal cortical tumors examined by flow cytometry, fluorescence in situ hybridization and immunohistochemistry. Int J Urol. 2005;12(2):121\u20137. https:\/\/doi.org\/10.1111\/j.1442-2042.2005.00999.x.","journal-title":"Int J Urol"},{"issue":"4","key":"9945_CR33","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1055\/s-2007-993164","volume":"116","author":"A Babinska","year":"2008","unstructured":"Babinska A, et al. The role of immunohistochemistry in histopathological diagnostics of clinically \u201csilent\u201d incidentally detected adrenal masses. Exp Clin Endocrinol Diabetes. 2008;116(4):246\u201351. https:\/\/doi.org\/10.1055\/s-2007-993164.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"5 B","key":"9945_CR34","first-page":"2959","volume":"28","author":"A Szajerka","year":"2008","unstructured":"Szajerka A, et al. Immunohistochemical evaluation of metallothionein, Mcm-2 and Ki-67 antigen expression in tumors of the adrenal cortex. Anticancer Res. 2008;28(5 B):2959\u201365.","journal-title":"Anticancer Res"},{"issue":"SUPPL. 1","key":"9945_CR35","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1186\/1471-2164-9-S1-S23","volume":"9","author":"JY Yang","year":"2008","unstructured":"Yang JY, et al. A hybrid machine learning-based method for classifying the Cushing\u2019s Syndrome with comorbid adrenocortical lesions. BMC Genomics. 2008;9(SUPPL. 1):S23. https:\/\/doi.org\/10.1186\/1471-2164-9-S1-S23.","journal-title":"BMC Genomics"},{"issue":"2","key":"9945_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4103\/0377-4929.155308","volume":"58","author":"G Mukherjee","year":"2015","unstructured":"Mukherjee G, et al. Histopathological study of adrenocortical masses with special references to Weiss score, Ki-67 index and p53 status. Indian J Pathol Microbiol. 2015;58(2):175\u201380. https:\/\/doi.org\/10.4103\/0377-4929.155308.","journal-title":"Indian J Pathol Microbiol"},{"issue":"7","key":"9945_CR37","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.prp.2017.03.004","volume":"213","author":"P Dalino Ciaramella","year":"2017","unstructured":"Dalino Ciaramella P, et al. Analysis of histological and immunohistochemical patterns of benign and malignant adrenocortical tumors by computerized morphometry. Pathol Res Pract. 2017;213(7):815\u201323. https:\/\/doi.org\/10.1016\/j.prp.2017.03.004.","journal-title":"Pathol Res Pract"},{"issue":"8","key":"9945_CR38","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1002\/jcb.25811","volume":"118","author":"SS Pereira","year":"2017","unstructured":"Pereira SS, et al. Telomerase and N-Cadherin differential importance in adrenocortical cancers and adenomas. J Cell Biochem. 2017;118(8):2064\u201371. https:\/\/doi.org\/10.1002\/jcb.25811.","journal-title":"J Cell Biochem"},{"issue":"3","key":"9945_CR39","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.21873\/anticanres.13224","volume":"39","author":"M Aporowicz","year":"2019","unstructured":"Aporowicz M, et al. Minichromosome maintenance proteins MCM-3, MCM-5, MCM-7, and Ki-67 as proliferative markers in adrenocortical tumors. Anticancer Res. 2019;39(3):1151\u20139. https:\/\/doi.org\/10.21873\/anticanres.13224.","journal-title":"Anticancer Res"},{"issue":"2","key":"9945_CR40","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s12022-020-09654-x","volume":"32","author":"SN Martins-Filho","year":"2021","unstructured":"Martins-Filho SN, et al. Clinical impact of pathological features including the Ki-67 labeling index on diagnosis and prognosis of adult and pediatric adrenocortical tumors. Endocr Pathol. 2021;32(2):288\u2013300. https:\/\/doi.org\/10.1007\/s12022-020-09654-x.","journal-title":"Endocr Pathol"},{"issue":"4","key":"9945_CR41","doi-asserted-by":"publisher","first-page":"814","DOI":"10.4103\/ijpm.ijpm_153_21","volume":"65","author":"P Maity","year":"2022","unstructured":"Maity P, et al. Diagnostic and prognostic utility of SF-1 in adrenal cortical tumours. Indian J Pathol Microbiol. 2022;65(4):814\u201320. https:\/\/doi.org\/10.4103\/ijpm.ijpm_153_21.","journal-title":"Indian J Pathol Microbiol"},{"issue":"8","key":"9945_CR42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529\u201336. https:\/\/doi.org\/10.7326\/0003-4819-155-8-201110180-00009.","journal-title":"Ann Intern Med"},{"issue":"7414","key":"9945_CR43","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"9945_CR44","unstructured":"Doebler PWM\u00a8unster, Holling H. Meta-analysis of diagnostic accuracy with mada.2015. https:\/\/cran.rproject.org\/web\/packages\/mada\/vignettes\/mada.pdf. Accessed Apr 2024."},{"issue":"3","key":"9945_CR45","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/jpm11030208","volume":"11","author":"A Angelousi","year":"2021","unstructured":"Angelousi A, et al. The role of immunohistochemical markers for the diagnosis and prognosis of adrenocortical neoplasms. J Personalized Med. 2021;11(3):208. https:\/\/doi.org\/10.3390\/jpm11030208.","journal-title":"J Personalized Med"},{"key":"9945_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae029","author":"D Chukkalore","year":"2024","unstructured":"Chukkalore D, et al. Adrenocortical carcinomas: molecular pathogenesis, treatment options, and emerging immunotherapy and targeted therapy approaches. Oncologist. 2024. https:\/\/doi.org\/10.1093\/oncolo\/oyae029.","journal-title":"Oncologist"},{"key":"9945_CR47","doi-asserted-by":"publisher","first-page":"819128","DOI":"10.3389\/fonc.2022.819128","volume":"12","author":"Y Peng","year":"2022","unstructured":"Peng Y, et al. PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway? Front Oncol. 2022;12:819128. https:\/\/doi.org\/10.3389\/fonc.2022.819128.","journal-title":"Front Oncol"},{"issue":"19","key":"9945_CR48","doi-asserted-by":"publisher","first-page":"10260","DOI":"10.3390\/ijms221910260","volume":"22","author":"C Stefani","year":"2021","unstructured":"Stefani C, et al. Growth Factors, PI3K\/AKT\/mTOR and MAPK signaling pathways in colorectal cancer pathogenesis: where are we now? Int J Mol Sci. 2021;22(19):10260. https:\/\/doi.org\/10.3390\/ijms221910260.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"9945_CR49","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3390\/biomedicines9020174","volume":"9","author":"M Mizdrak","year":"2021","unstructured":"Mizdrak M, Ticinovic Kurir T, Bozic J. The role of biomarkers in adrenocortical carcinoma: a review of current evidence and future perspectives. Biomedicines. 2021;9(2):174. https:\/\/doi.org\/10.3390\/biomedicines9020174.","journal-title":"Biomedicines"},{"issue":"7","key":"9945_CR50","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1007\/s12094-020-02524-2","volume":"23","author":"S Minner","year":"2021","unstructured":"Minner S, Schreiner J, Saeger W. Adrenal cancer: relevance of different grading systems and subtypes. Clin Transl Oncol. 2021;23(7):1350\u20137. https:\/\/doi.org\/10.1007\/s12094-020-02524-2.","journal-title":"Clin Transl Oncol"},{"issue":"11","key":"9945_CR51","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1038\/s41379-018-0071-1","volume":"31","author":"C Koppel","year":"2018","unstructured":"Koppel C, et al. Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28\u20138 on different staining platforms. Mod Pathol. 2018;31(11):1630\u201344. https:\/\/doi.org\/10.1038\/s41379-018-0071-1.","journal-title":"Mod Pathol"},{"issue":"11","key":"9945_CR52","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1136\/jcp.2007.047720","volume":"61","author":"G Bussolati","year":"2008","unstructured":"Bussolati G, Leonardo E. Technical pitfalls potentially affecting diagnoses in immunohistochemistry. J Clin Pathol. 2008;61(11):1184\u201392. https:\/\/doi.org\/10.1136\/jcp.2007.047720.","journal-title":"J Clin Pathol"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-025-09945-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-025-09945-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-025-09945-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T05:05:32Z","timestamp":1742274332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-025-09945-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["9945"],"URL":"https:\/\/doi.org\/10.1007\/s11154-025-09945-w","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"16 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have nothing to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/Competing interests"}}]}}